Telmisartan (Telmisartanum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Angiotensin II receptor antagonists (AT1 subtype)

Included in the formulation
  • Mycardis®
    pills inwards 
    Boehringer Ingelheim International GmbH     Germany
  • Theseo®
    pills inwards 
    Zentiva c.s.     Czech Republic
  • Telmisartan
    pills inwards 
    ATOLL, LLC     Russia
  • TELMISARTAN-RICHTER
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Telmisartan-SZ
    pills inwards 
    NORTH STAR, CJSC     Russia
  • Telmist®
    pills
    KRKA, dd, Novo mesto, AO    
  • Telpres
    pills inwards 
    SiNViTi Pharma Co., Ltd.     Cyprus
  • Telsartan®
    pills inwards 
    Dr. Reddy's Laboratories Ltd.     India
    • АТХ:

    C.09.C.A.07   Telmisartan

    Pharmacodynamics:

    Angiotensin II receptor antagonist selectively binds to AT1receptors in the vessels, the adrenal cortex, the heart and the kidneys. Prevents the effect of angiotensin II on renal blood flow and blood pressure.

    Does not affect the concentration in the blood plasma of low-density lipoproteins, triglycerides and glucose. Improves renal blood flow, without affecting the mechanisms of self-regulation of the kidneys. In patients with healthy kidneys, increases natriuresis and does not cause retention of sodium ions in patients with renal insufficiency.

    Has hypotensive, vasodilating, nephroprotective effect, reducing the excretion of albumins, increases the rate of glomerular filtration and renal blood flow.With prolonged use suppresses the proliferation of smooth muscle vessels and myocardium, caused by angiotensin II.

    The hypotensive effect after taking the drug continues for 24 hours, with regular admission a stable therapeutic effect is established after 2-3 weeks and is not accompanied by an increase in heart rate. Does not cause withdrawal syndrome after discontinuation.

    Pharmacokinetics:

    After oral administration, an empty stomach is absorbed in the gastrointestinal tract up to 50%. The maximum concentration in the blood plasma is achieved after 0.5-1.5 hours. The connection with plasma proteins is 99.5%.

    Metabolism in the liver.

    The half-life is 20 hours. Elimination by the kidneys.

    Indications:

    It is used for the treatment of arterial hypertension.

    ICD-10

    IX.I10-I15.I15   Secondary Hypertension

    IX.I10-I15.I10   Essential [primary] hypertension

    Contraindications:

    Stenosis of an artery of a unique kidney, a primary aldosteronism, an individual intolerance, a children's age till 12 years.

    Carefully:

    Adolescence, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside, 20-40 mg per day in the morning, regardless of food intake. If necessary, the dose is doubled, to 80 mg.

    The highest daily dose: 80 mg.

    The highest single dose: 80 mg.

    Side effects:

    Central and peripheral nervous system: headache, dizziness, asthenia.

    Respiratory system: cough, rhinitis, pharyngitis.

    The cardiovascular system: postural hypotension.

    Musculoskeletal system: myalgia.

    Digestive system: dyspeptic disorders, vomiting, diarrhea.

    Allergic reactions.

    Overdose:

    Arterial hypotension.

    Treatment is symptomatic. Hemodialysis is ineffective.
    Interaction:

    At simultaneous application with blockers of slow calcium channels and thiazide diuretics, a mutual enhancement of hypotensive effect is observed.

    When used simultaneously with non-steroidal anti-inflammatory drugs, there is a chance of developing acute renal failure.

    Special instructions:

    Monitoring of kidney function.

    In the first days of taking the drug is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up